Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

doctor examines patient data on their tablet

TAVR or SAVR? ChatGPT could help cardiologists decide

Researchers asked ChatGPT to make treatment decisions for patients with severe aortic stenosis, comparing its answers to the recommendations of a full heart team. 

TAVR JenaValve Trilogy Heart Valve System pure AR

Cardiologists make history, perform first-ever transcaval TAVR for pure aortic regurgitation

The 65-year-old male patient presented with a long medical history and many comorbidities, making surgery too risky.

Cardiologist heart

Q&A: Interventional cardiologist details key breakthroughs in tricuspid valve replacement and repair

How have recent FDA approvals for Edwards Lifesciences and Abbott changed patient care? Andrew Rassi, MD, answered that question—and many more—in a new interview. 

PHOTO GALLERY: Highlights from ACC.24 in Atlanta

ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement. 

Video of Howard Herrmann, MD, explaining the details of the SMART trial that looked at TAVR in small annulus and found self-expanding TAVR valves work better in these patients than balloon-expanding TAVR.

Cardiologist highlights key takeaways from SMART trial, which looked at TAVR in small annulus patients

Howard C. Herrmann, MD, principal investigator of the SMART trial, discussed his team's research on self-expanding vs. balloon-expandable TAVR valves in patients with small annuli. 

doctor examines patient data on their tablet

TAVR, SAVR both linked to low reintervention rates after five years

While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

Newsweek ranked the 50 best heart hospitals in the world

ACC.24: TAVR linked to lower 1-year mortality, stroke rates than SAVR in low-risk patients

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

ACC.24 late-breaking clinical trials

ACC.24: Self-expanding Evolut valves offer superior performance for TAVR patients with small annuli

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup